Efficacy and safety of norfloxacin 800 mg once-daily versus norfloxacin 400 mg twice-daily in the treatment of uncomplicated urinary tract infections in women: A double-blind, randomized clinical trial

Journal of Chemotherapy

Volumn 10, Issue 2, 1998, Pages 122-127

  Pimentel, F L ^a,b   Dolgner, A ^b   Guimaraes J ^a   Quintas, M ^a   Mario Reis J ^a  

^a HOSPITAL DE SÃO JOÃO   (Portugal)

^b DEPARTMENT OF RESEARCH AND DEVELOPMENT   (Portugal)

Author keywords

Clinical trial; Norfloxacin; Quinolones; Urinary tract infection

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; CEFIXIME; GENTAMICIN; NITROFURANTOIN; NORFLOXACIN;

ABDOMINAL PAIN; ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSURIA; ENTEROCOCCUS; ESCHERICHIA COLI; FEMALE; FEVER; GRAM NEGATIVE BACTERIUM; HEMATURIA; HUMAN; IN VITRO STUDY; LEUKOCYTURIA; MAJOR CLINICAL STUDY; MICTURITION DISORDER; NAUSEA; ORAL DRUG ADMINISTRATION; PROTEINURIA; PROTEUS MIRABILIS; RANDOMIZED CONTROLLED TRIAL; STAPHYLOCOCCUS; TABLET; URINARY TRACT INFECTION; URINE SEDIMENT; VERTIGO; VOMITING;

EID: 0031944261     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.1998.10.2.122     Document Type: Article

References (30)

1. Sanders CC, Wise R, Weston D, et al. Selection of multiple antibiotic resistance by quinolones, β-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes. Antimicrob Agents Chemother 1984; 13: 797-801.
2. Adhami ZN. The pharmacokinetics and tissue penetration of norfloxacin. J Antimicrob Chemother 1984; 13: 87-92.
3. Hughes PJ, Webb DB, Asscher W. Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function - some preliminary results. J Antimicrob Chemother 1984;13 (Suppl B) 55-57.
4. Stein GE. Review of the bioavailability and pharmacokinetics of oral norfloxacin. Am J Med 1987; 82 (Suppl 6B): 18-21.
5. Bailey RR, Peddie BA, Blake E. Norfloxacin for the treatment of uncomplicated urinary tract infections. NZ Med J 1983; 8: 446.
6. Boerema JBJ, Van Saene HK. Norfloxacin treatment in complicated urinary tract infection. Scand J Infect Dis 1986; Suppl 48: 20-26.
7. Deamey NB, Vogel R, Vanderburg MJ. Norfloxacin in acute urinary tract infections. Practitioner 1984; 228: 111-117.
8. Lee C. Norfloxacin: its potential in clinical practice. Am J Med 1987; 82 (suppl 6B): 27-34.
9. Ramirez-Ronda, Colon I, Saavedra S, et al. Treatment of urinary tract infection with norfloxacin. Analysis of cost. Am J Med 1987; 82 (suppl 6B): 75-78.
10. Schaeffer AJ. Multiclinic study of norfloxacin for treatment of urinary tract infections. Am J Med 1987; 82 (suppl 6B): 53-58.
11. Hussar DA. Importance of patient compliance in effective antimicrobial therapy. Pediatr Infect Dis J 1987; 6: 971-975.
12. Pullar T. Use of pharmacologic indicator to compare compliance with tablets prescribed once, twice or three times daily. Clin Pharmacol Ther 1988, 44 (59): 540-545.
13. Swanson BN, Boppana BK, Vlasse PH, et al. Norfloxacin disposition after sequentially increasing oral doses. Antimicrob Agents Chemother 1983; 23: 284-288.
14. Guimarães M, Pimentel FL, Quintas J, et al. Evaluation of the tolerability of a single daily 800 mg dose of norfloxacin. J Chemother 1993; 5 (suppl 1): 359-360.
15. Smith JT. The mode of action of 4-quinolones and possible mechanisms of resistance. J Antimicrob Chemother 1986; 18: 21-29.
16. Mascellino MT, Lorenzi A, Bonanni M, et al. Antimicrobial activity of norfloxacin in enteric and urinary tract infections: combined effect of norfloxacin with aminoglycosides, tetracycline and chloramphenicol. Drugs Exptl Clin Res 1986; 319-323.
17. Norrby SR, Jonsson M. Antibacterial activity of norfloxacin. Antimicrob Agents Chemother 1983; 23: 15-18.
18. Pantosti A, Giuliano M, Testore GP, et al. Microbiological and clinical study on a new chemotherapeutic agent for urinary tract infections: MK-0366. Drugs Exptl Clin Res 1984; X: 43-45.
19. Wise RJ. Norfloxacin - a review of pharmacology and tissue penetration. Antimicrob Chemother 1984; 13 (suppl B): 59-64.
20. Cofsky RD. Recovery of norfloxacin in feces after administration of a single oral dose to human volunteers. Antimicrob Agents Chemother 1984; 26: 110-111.
21. Goldenstein JC. Norfloxacin, a fluoroquinolone antibacterial agent. Classification, mechanism of action and in vitro activity. Am J Med 1987: 82 (suppl 6B): 3-17.
22. Shungu DL, Weinberg E, Gadebusch HH. In vitro antibacterial activity of norfloxacin (MK-0366, AM-715) and other agents against gastrointestinal tract pathogens. Antimicrob Agents Chemother 1983; 23: 86-90.
23. De Vevey P, Darioli R, Bille J, et al. Étude comparative du traitement de l'infection urinaire simple par une dose unique de norfloxacine versus cotrimoxazole. Schweiz Med Wschr 1987; 117: 968-973.
24. Del Favero A, Mencheti F, Guerciolini NI, et al. Norfloxacin versus pipemidic acid in complicated urinary tract infections due to susceptible pathogens: a comparative clinical trial. Chemioterapia 1986; 5: 88-91.
25. Giamarellou H, Tsagarakis J, Petrikkos, et al. Norfloxacin versus cotrimoxazole in the treatment of lower urinary tract infections. Eur J Clin Microbiol 1983; 2: 266-269.
26. th Int Cong Chemother Vienna. 1983: (Tom 5), 38: 25-30.
27. Sabbaj J, Hoagland VL, Shih WJ. Multicentric comparative study of norfloxacin and trimethoprim-sulfamethoxazole for treatment of urinary tract infections. Antimicrob Agents Chemother 1985; 27: 297-301.
28. Sabbaj J, Hoagland VL, Cook T, et al. Norfloxacin versus co-trimoxazole in the treatment of recurring urinary tract infections in man. Scand J Infect Dis 1986; Suppl 48: 48-53.
29. Corrado ML, Struble WE, Peter C. Norfloxacin: Review of safety studies. Am J Med 1987;82 (suppl 6B):22-26.
30. Wang C, Sabbaj J, Corrado M, et al. Worldwide clinical experience with norfloxacin: Efficacy and safety. Scand J Infect Dis 1986; Suppl 48: 81-89.